These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33077847)

  • 21. Clinical Application of Next-Generation Sequencing-Based Panel to
    Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS
    Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
    Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
    J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
    Eckardt J; Schroeder C; Martus P; Armeanu-Ebinger S; Kelemen O; Gschwind A; Bonzheim I; Eigentler T; Amaral T; Ossowski S; Rieß O; Flatz L; Garbe C; Forschner A
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):833-840. PubMed ID: 35192052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients.
    Tas F; Erturk K
    Neoplasma; 2019 Jul; 66(4):631-636. PubMed ID: 31058533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma.
    Hotz MJ; O'Halloran EA; Hill MV; Hayden K; Zaladonis AG; Deng M; Olszanski AJ; Reddy SS; Wu H; Luo B; Farma JM
    Melanoma Res; 2022 Apr; 32(2):112-119. PubMed ID: 35213415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha.
    Tas F; Erturk K
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):521-526. PubMed ID: 30997532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MC1R germline variants confer risk for BRAF-mutant melanoma.
    Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
    Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.
    Mordoh A; Triviño Pardo JC; Carri I; Barrio MM; Mordoh J; Aris M
    BMC Med Genomics; 2023 Jan; 16(1):1. PubMed ID: 36604730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
    Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
    Jurkowska M; Gos A; Ptaszyński K; Michej W; Tysarowski A; Zub R; Siedlecki JA; Rutkowski P
    Int J Clin Exp Pathol; 2015; 8(7):8487-93. PubMed ID: 26339422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.
    Bucheit AD; Syklawer E; Jakob JA; Bassett RL; Curry JL; Gershenwald JE; Kim KB; Hwu P; Lazar AJ; Davies MA
    Cancer; 2013 Nov; 119(21):3821-9. PubMed ID: 23922205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma.
    Meckbach D; Bauer J; Pflugfelder A; Meier F; Busch C; Eigentler TK; Capper D; von Deimling A; Mittelbronn M; Perner S; Ikenberg K; Hantschke M; Büttner P; Garbe C; Weide B
    PLoS One; 2014; 9(1):e86194. PubMed ID: 24475086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. POLE mutations in families predisposed to cutaneous melanoma.
    Aoude LG; Heitzer E; Johansson P; Gartside M; Wadt K; Pritchard AL; Palmer JM; Symmons J; Gerdes AM; Montgomery GW; Martin NG; Tomlinson I; Kearsey S; Hayward NK
    Fam Cancer; 2015 Dec; 14(4):621-8. PubMed ID: 26251183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
    Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
    J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of vemurafenib in patients with BRAF
    Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
    Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
    Hauschild A; Dummer R; Schadendorf D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Haas T; Shilkrut M; Gasal E; Kefford R; Kirkwood JM; Long GV
    J Clin Oncol; 2018 Dec; 36(35):3441-3449. PubMed ID: 30343620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
    Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
    J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
    [No Abstract]   [Full Text] [Related]  

  • 40. Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma.
    Schreuer M; Meersseman G; van Den Herrewegen S; Jansen Y; Seremet T; Bott A; Chevolet I; Wilgenhof S; Maertens G; Neyns B
    Melanoma Res; 2016 Apr; 26(2):157-63. PubMed ID: 26636909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.